Immunohistochemical detections of EGFR mutations in NSCLC

In recent years, it has been well known that non-small cell lung cancer (NSCLC) patients with mutations of epidermal growth factor receptor (EGFR) response better to EGFR-tyrosine kinase inhibitor treatment. Although DNA-based assays (e.g. DNA sequencing) are the most frequently used and a relativel...

Full description

Saved in:
Bibliographic Details
Published in:Zhongguo fei ai za zhi 2014-09, Vol.17 (9), p.701-705
Main Authors: Liu, Chang, Xu, Dongbo, Zhong, Diansheng
Format: Article
Language:Chinese
Subjects:
Cancer therapies
Carcinoma, Non-Small-Cell Lung - enzymology
Carcinoma, Non-Small-Cell Lung - genetics
DNA Mutational Analysis - methods
Epidermal growth factor
Epidermal growth factor receptor
Humans
Immunoglobulins
Immunohistochemistry
Immunohistochemistry - methods
Lung cancer
Lung neoplasms
Lung Neoplasms - enzymology
Lung Neoplasms - genetics
Mutation
Receptor, Epidermal Growth Factor - genetics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 705
container_issue 9
container_start_page 701
container_title Zhongguo fei ai za zhi
container_volume 17
creator Liu, Chang
Xu, Dongbo
Zhong, Diansheng
description In recent years, it has been well known that non-small cell lung cancer (NSCLC) patients with mutations of epidermal growth factor receptor (EGFR) response better to EGFR-tyrosine kinase inhibitor treatment. Although DNA-based assays (e.g. DNA sequencing) are the most frequently used and a relatively reliable method to detect EGFR mutations, they are complex, time-consuming and relatively expensive for routine use in clinical laboratories, besides they require high quality tumor samples. In contrast, the immunohistochemistry (IHC) methods make up fully for the above shortcomings and can serve as screening tests for EGFR mutations. However, there are many factors that can influence the results of IHC methods, such as different staining procedures, different antigen retrieval solutions and different sets of criteria, etc. Thus the IHC methods for detecting EGFR mutations have not been widely used in clinic and only in the research stage. This article reviews the use of IHC methods by different researchers and f
doi_str_mv 10.3779/j.issn.1009-3419.2014.09.11
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_30704665c3134c8d9ff77fcf6a25e4a2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_30704665c3134c8d9ff77fcf6a25e4a2</doaj_id><sourcerecordid>2126944263</sourcerecordid><originalsourceid>FETCH-LOGICAL-d253t-59b2b2a6c9d9cea3bb19892c1b4188bca8b01882e0144266a8f0a3aca1973f573</originalsourceid><addsrcrecordid>eNqFkUtr3EAQhAeT4FfyF4LAF1-kTPc8-2gW21lYYnCSsxiNRvEsksbWSIf8-8hZ2wdfcuqi-CioLsYugFfCGPq6r2LOYwWcUykkUIUcZMWpAjhip0BEpQZrPqz6FTlhZznvOddIQh6zE1QorQF5ymg7DMuYHmKek38IQ_SuL9owBz_HNOYidcX17c19MSyzOzhxLL7_2Ow2n9jHzvU5fH655-zXzfXPzbdyd3e73VztyhaVmEtFDTbotKeWfHCiaYAsoYdGgrWNd7bhq8CwlpCotbMdd8J5B2REp4w4Z9tDbpvcvn6c4uCmP3Vysf5npOl37aY5-j7UghsutVZegJDettR1xnS-0w5VkA7XrMtD1uOUnpaQ53qI2Ye-d2NIS67BorFWWYD_o0orxRHpGb14h-7TMo3rU2oE1PTcS6zUlxdqaYbQvjV53UL8Bb52ir0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2126944263</pqid></control><display><type>article</type><title>Immunohistochemical detections of EGFR mutations in NSCLC</title><source>PubMed Central (PMC)</source><source>Publicly Available Content (ProQuest)</source><creator>Liu, Chang ; Xu, Dongbo ; Zhong, Diansheng</creator><creatorcontrib>Liu, Chang ; Xu, Dongbo ; Zhong, Diansheng</creatorcontrib><description>In recent years, it has been well known that non-small cell lung cancer (NSCLC) patients with mutations of epidermal growth factor receptor (EGFR) response better to EGFR-tyrosine kinase inhibitor treatment. Although DNA-based assays (e.g. DNA sequencing) are the most frequently used and a relatively reliable method to detect EGFR mutations, they are complex, time-consuming and relatively expensive for routine use in clinical laboratories, besides they require high quality tumor samples. In contrast, the immunohistochemistry (IHC) methods make up fully for the above shortcomings and can serve as screening tests for EGFR mutations. However, there are many factors that can influence the results of IHC methods, such as different staining procedures, different antigen retrieval solutions and different sets of criteria, etc. Thus the IHC methods for detecting EGFR mutations have not been widely used in clinic and only in the research stage. This article reviews the use of IHC methods by different researchers and f</description><identifier>ISSN: 1009-3419</identifier><identifier>EISSN: 1999-6187</identifier><identifier>DOI: 10.3779/j.issn.1009-3419.2014.09.11</identifier><identifier>PMID: 25248714</identifier><language>chi</language><publisher>China: Chinese Anti-Cancer Association Chinese Antituberculosis Association</publisher><subject>Cancer therapies ; Carcinoma, Non-Small-Cell Lung - enzymology ; Carcinoma, Non-Small-Cell Lung - genetics ; DNA Mutational Analysis - methods ; Epidermal growth factor ; Epidermal growth factor receptor ; Humans ; Immunoglobulins ; Immunohistochemistry ; Immunohistochemistry - methods ; Lung cancer ; Lung neoplasms ; Lung Neoplasms - enzymology ; Lung Neoplasms - genetics ; Mutation ; Receptor, Epidermal Growth Factor - genetics</subject><ispartof>Zhongguo fei ai za zhi, 2014-09, Vol.17 (9), p.701-705</ispartof><rights>Copyright © 2014. This work is published under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2126944263/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2126944263?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25752,27923,27924,37011,37012,44589,74897</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25248714$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Chang</creatorcontrib><creatorcontrib>Xu, Dongbo</creatorcontrib><creatorcontrib>Zhong, Diansheng</creatorcontrib><title>Immunohistochemical detections of EGFR mutations in NSCLC</title><title>Zhongguo fei ai za zhi</title><addtitle>Zhongguo Fei Ai Za Zhi</addtitle><description>In recent years, it has been well known that non-small cell lung cancer (NSCLC) patients with mutations of epidermal growth factor receptor (EGFR) response better to EGFR-tyrosine kinase inhibitor treatment. Although DNA-based assays (e.g. DNA sequencing) are the most frequently used and a relatively reliable method to detect EGFR mutations, they are complex, time-consuming and relatively expensive for routine use in clinical laboratories, besides they require high quality tumor samples. In contrast, the immunohistochemistry (IHC) methods make up fully for the above shortcomings and can serve as screening tests for EGFR mutations. However, there are many factors that can influence the results of IHC methods, such as different staining procedures, different antigen retrieval solutions and different sets of criteria, etc. Thus the IHC methods for detecting EGFR mutations have not been widely used in clinic and only in the research stage. This article reviews the use of IHC methods by different researchers and f</description><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - enzymology</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>DNA Mutational Analysis - methods</subject><subject>Epidermal growth factor</subject><subject>Epidermal growth factor receptor</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Immunohistochemistry</subject><subject>Immunohistochemistry - methods</subject><subject>Lung cancer</subject><subject>Lung neoplasms</subject><subject>Lung Neoplasms - enzymology</subject><subject>Lung Neoplasms - genetics</subject><subject>Mutation</subject><subject>Receptor, Epidermal Growth Factor - genetics</subject><issn>1009-3419</issn><issn>1999-6187</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqFkUtr3EAQhAeT4FfyF4LAF1-kTPc8-2gW21lYYnCSsxiNRvEsksbWSIf8-8hZ2wdfcuqi-CioLsYugFfCGPq6r2LOYwWcUykkUIUcZMWpAjhip0BEpQZrPqz6FTlhZznvOddIQh6zE1QorQF5ymg7DMuYHmKek38IQ_SuL9owBz_HNOYidcX17c19MSyzOzhxLL7_2Ow2n9jHzvU5fH655-zXzfXPzbdyd3e73VztyhaVmEtFDTbotKeWfHCiaYAsoYdGgrWNd7bhq8CwlpCotbMdd8J5B2REp4w4Z9tDbpvcvn6c4uCmP3Vysf5npOl37aY5-j7UghsutVZegJDettR1xnS-0w5VkA7XrMtD1uOUnpaQ53qI2Ye-d2NIS67BorFWWYD_o0orxRHpGb14h-7TMo3rU2oE1PTcS6zUlxdqaYbQvjV53UL8Bb52ir0</recordid><startdate>20140920</startdate><enddate>20140920</enddate><creator>Liu, Chang</creator><creator>Xu, Dongbo</creator><creator>Zhong, Diansheng</creator><general>Chinese Anti-Cancer Association Chinese Antituberculosis Association</general><general>Chinese Anti-Cancer Association; Chinese Antituberculosis Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BVBZV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope><scope>DOA</scope></search><sort><creationdate>20140920</creationdate><title>Immunohistochemical detections of EGFR mutations in NSCLC</title><author>Liu, Chang ; Xu, Dongbo ; Zhong, Diansheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d253t-59b2b2a6c9d9cea3bb19892c1b4188bca8b01882e0144266a8f0a3aca1973f573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2014</creationdate><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - enzymology</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>DNA Mutational Analysis - methods</topic><topic>Epidermal growth factor</topic><topic>Epidermal growth factor receptor</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Immunohistochemistry</topic><topic>Immunohistochemistry - methods</topic><topic>Lung cancer</topic><topic>Lung neoplasms</topic><topic>Lung Neoplasms - enzymology</topic><topic>Lung Neoplasms - genetics</topic><topic>Mutation</topic><topic>Receptor, Epidermal Growth Factor - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Chang</creatorcontrib><creatorcontrib>Xu, Dongbo</creatorcontrib><creatorcontrib>Zhong, Diansheng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>East &amp; South Asia Database</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Zhongguo fei ai za zhi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Chang</au><au>Xu, Dongbo</au><au>Zhong, Diansheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunohistochemical detections of EGFR mutations in NSCLC</atitle><jtitle>Zhongguo fei ai za zhi</jtitle><addtitle>Zhongguo Fei Ai Za Zhi</addtitle><date>2014-09-20</date><risdate>2014</risdate><volume>17</volume><issue>9</issue><spage>701</spage><epage>705</epage><pages>701-705</pages><issn>1009-3419</issn><eissn>1999-6187</eissn><abstract>In recent years, it has been well known that non-small cell lung cancer (NSCLC) patients with mutations of epidermal growth factor receptor (EGFR) response better to EGFR-tyrosine kinase inhibitor treatment. Although DNA-based assays (e.g. DNA sequencing) are the most frequently used and a relatively reliable method to detect EGFR mutations, they are complex, time-consuming and relatively expensive for routine use in clinical laboratories, besides they require high quality tumor samples. In contrast, the immunohistochemistry (IHC) methods make up fully for the above shortcomings and can serve as screening tests for EGFR mutations. However, there are many factors that can influence the results of IHC methods, such as different staining procedures, different antigen retrieval solutions and different sets of criteria, etc. Thus the IHC methods for detecting EGFR mutations have not been widely used in clinic and only in the research stage. This article reviews the use of IHC methods by different researchers and f</abstract><cop>China</cop><pub>Chinese Anti-Cancer Association Chinese Antituberculosis Association</pub><pmid>25248714</pmid><doi>10.3779/j.issn.1009-3419.2014.09.11</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1009-3419
ispartof Zhongguo fei ai za zhi, 2014-09, Vol.17 (9), p.701-705
issn 1009-3419
1999-6187
language chi
recordid cdi_doaj_primary_oai_doaj_org_article_30704665c3134c8d9ff77fcf6a25e4a2
source PubMed Central (PMC); Publicly Available Content (ProQuest)
subjects Cancer therapies
Carcinoma, Non-Small-Cell Lung - enzymology
Carcinoma, Non-Small-Cell Lung - genetics
DNA Mutational Analysis - methods
Epidermal growth factor
Epidermal growth factor receptor
Humans
Immunoglobulins
Immunohistochemistry
Immunohistochemistry - methods
Lung cancer
Lung neoplasms
Lung Neoplasms - enzymology
Lung Neoplasms - genetics
Mutation
Receptor, Epidermal Growth Factor - genetics
title Immunohistochemical detections of EGFR mutations in NSCLC
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T13%3A59%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunohistochemical%20detections%20of%20EGFR%20mutations%20in%20NSCLC&rft.jtitle=Zhongguo%20fei%20ai%20za%20zhi&rft.au=Liu,%20Chang&rft.date=2014-09-20&rft.volume=17&rft.issue=9&rft.spage=701&rft.epage=705&rft.pages=701-705&rft.issn=1009-3419&rft.eissn=1999-6187&rft_id=info:doi/10.3779/j.issn.1009-3419.2014.09.11&rft_dat=%3Cproquest_doaj_%3E2126944263%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d253t-59b2b2a6c9d9cea3bb19892c1b4188bca8b01882e0144266a8f0a3aca1973f573%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2126944263&rft_id=info:pmid/25248714&rfr_iscdi=true